Cancer recurrence and metastasis are life threatening condition to cancer patients. Although adjuvant chemotherapy is used to prevent recurrence, the preventive effects are unsatisfactory and cancer patients suffer from several side effects. There is a need for drugs have higher cancer prevention effects but lower side effects.
In silico assay, which can facilitate the rate of the appropriate drug discovery for specific disease by computer simulation, has been rapidly developing. As using in silico assay, we discovered OC-201 by comparing differences of gene expression patterns between colon adenoma and colon carcinoma, between poor prognosis colon cancer patients and good prognosis colon cancer patients. Also, OC-202, which is complementary role to OC-201, was also discovered. Anti-invasion and anti-metastasis effect of both OC-201 and OC-202 drugs have been evaluated in colon cancer, biliary cancer and pancreatic cancer in vitro and in vivo.
At non-toxic concentrations in colon cancer cells, OC-201 and OC-202 suppressed colon cancer cells invasion and migration, which is a crucial mechanism associated with cancer metastasis. Co-treatment of OC-201 and OC-202 showed synergic anti-invasion and anti-migration effect compared to alone. In addition, OC-201 and OC-202 also suppressed colony formation by soft agar assay which is the method measured anchorage independent growth. These drugs regulated that epithelial to mesenchymal transition markers such as vimentin and N-cadherin. In vivo experiments, OC-201 and OC-202 decreased number of lung metastasis up to 70% in mouse colon cancer xenograft model. Intriguingly, OC-201 and OC-202 showed same results in biliary cancer and pancreas cancer cell lines. OC-201 and OC-202 co-treatment is more effective than alone in all data and cancer types.
OC-201 and OC-202 could be potent metastasis inhibitors via blocking cancer cell invasion and migration by regulating EMT.
Clinical trial identification
Legal entity responsible for the study
Has not received any funding.
H.J. Na, S.Y. Park, S.J. Lee: Employee: Oncocross which is a pharmaceutical company. Y.R. Kim: CEO: Oncocross which is a pharmaceutical company. All other authors have declared no conflicts of interest.